Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease

(2018) Shan Li et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance

(2018) Xuan Du et al.   Journal of Diabetes Research

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial

(2018) Ting-Ting Yin et al.   Diabetes Therapy

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial

(2018) Ting-Ting Yin et al.   Diabetes Therapy

GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis

(2018) Marco Castellana et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Validation of a free software for unsupervised assessment of abdominal fat in MRI

(2017) Michele Maddalo et al.   Physica Medica-European Journal of Medical Physics

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

(2016) K. Cusi et al.   DIABETES OBESITY & METABOLISM

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

(2016) S. Mudaliar et al.   DIABETES OBESITY & METABOLISM

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

(2016) Kenneth Cusi   DIABETOLOGIA

Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016

(2016) Dharmesh H. Kaswala et al.   DIGESTIVE DISEASES AND SCIENCES

Nonalcoholic Fatty Liver Disease

(2016) Fernando Bril et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

(2016) Kento Imajo et al.   GASTROENTEROLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Effect of Insulin Versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes

(2016) Ildiko Lingvay et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids

(2015) Daniel F. Vatner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

(2014) Yan Bi et al.   ACTA DIABETOLOGICA

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

(2014) Hui Fan et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)

(2014) W. Xu et al.   JOURNAL OF INTERNAL MEDICINE

Hepatoselectivity and the evolution of insulin

(2013) R. Herring et al.   DIABETES OBESITY & METABOLISM

Prevalence and Control of Diabetes in Chinese Adults

(2013) Yu Xu   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(2012) Daniel J. Cuthbertson et al.   PLoS One

Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method

(2011) Ming-Feng Xia et al.   Obesity

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

(2011) Padma Sathyanarayana et al.   Obesity

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham heart study

(2010) Elizabeth K. Speliotes et al.   HEPATOLOGY

Exenatide: A new promising antidiabetic agent

(2010) CK Chakraborti   INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES

Exenatide and weight loss

(2010) David P. Bradley et al.   NUTRITION

Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes

(2009) T. Okerson et al.   AMERICAN JOURNAL OF HYPERTENSION

Epidemiology and Natural History of Non-Alcoholic Steatohepatitis

(2009) Curtis K. Argo et al.   Clinics in Liver Disease